Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse 16:01:42 2024-09-20 EDT 5-day change 1st Jan Change
117.17 USD -0.05% Intraday chart for Merck & Co., Inc. +1.13% +7.48%
LockThis article is reserved for members
To unlock the article, REGISTER!
Vous êtes déja client ? Log In
Merck Receives Positive EU CHMP Opinions for Keytruda in Gynecologic Cancers MT
Merck Gets European Panel Backing for Keytruda in Two Gynecologic Cancers DJ
Merck Secures FDA Approval for Keytruda Combination Therapy as Malignant Pleural Mesothelioma Treatment MT
Merck Gets First FDA Approval of Keytruda in Malignant Pleural Mesothelioma DJ
Merck: Keytruda approved for pleural mesothelioma CF
FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma CI
Merck & Co., Inc. Presents at Bank of America Global Healthcare Conference 2024, Sep-18-2024 10:40 AM
Daiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets Primary Endpoint DJ
Merck's Lung Cancer Drug Meets Primary Endpoint in Late-Stage Study MT
Merck Says 10-Year Keytruda Phase 3 Trial Results Show Sustained Survival MT
Merck Says Keytruda With Chemoradiotherapy Lowers Risk of Death in Cervical Cancer Trial MT
Merck Says Keytruda Combination Improved Overall Survival for Breast Cancer Patients in Phase 3 Trial MT
Merck Announces the First-Time Presentation of Overall Survival (OS) Results from the Phase 3 KEYNOTE-522 Trial Evaluating KEYTRUDA® (Pembrolizumab) CI
Merck Announces Long-Term Overall Survival Data from the Pivotal Phase 3 KEYNOTE-006 Trial, Evaluating KEYTRUDA® (Pembrolizumab) CI
Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab) CI
Merck Announces the First Presentation of Overall Survival Results from the Pivotal Phase 3 KEYNOTE-A18 trial CI
Merck Announces Overall Survival Results from the Final Analysis of the Phase 3 Keynote-811 Trial Evaluating Keytruda® (Pembrolizumab) CI
Merck Says Health Canada Approved Keytruda as Treatment for Hard-to-Treat Solid Tumors MT
Merck: positive results for HPV vaccine CF
Merck's HPV Vaccine Meets Main Goal in Phase 3 Study in Japanese Males MT
Phanes Therapeutics Doses First Patient in Trial of Pancreatic Cancer Treatment in Combination With Chemotherapy MT
Merck: positive results in certain lung cancers CF
Veeva Systems: leader in cloud solutions for the life sciences industry Our Logo
US Equities Markets End Mixed Thursday as Investors Evaluate Job Growth Report MT
Sector Update: Health Care Stocks Fall Late Afternoon MT
Chart Merck & Co., Inc.
More charts
Logo Merck & Co., Inc.
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Employees
71,000
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
117.17USD
Average target price
139.03USD
Spread / Average Target
+18.65%
Consensus
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. News Merck & Co., Inc.
  5. Top Midday Stories: June US Job Openings Drop; Merck Cuts 2024 Non-GAAP EPS Forecast; Pfizer Adjusted Earnings Fall; Procter & Gamble Net Sales Decline; S&P Global Reports Higher Results, Lifts Fiscal 2024 Outlook; BP Underlying Earnings Gain; Meta Platforms to Pay $1.4 Billion to Settle Texas Facial Recognition Data Suit